Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

NCT04655157 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Study terminated due to slow enrollment

Conditions

Melanoma

Interventions

DRUG: encorafenib
DRUG: nivolumab
DRUG: ipilimumab
DRUG: binimetinib

Sponsor

Jason J. Luke, MD

Collaborators

[object Object]